Barclays PLC grew its position in ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report) by 1,124.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,522 shares of the company’s stock after purchasing an additional 38,132 shares during the quarter. Barclays PLC’s holdings in ArriVent BioPharma were worth $976,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Novo Holdings A S lifted its holdings in shares of ArriVent BioPharma by 39.3% during the second quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock worth $27,825,000 after buying an additional 422,860 shares during the last quarter. Geode Capital Management LLC increased its position in ArriVent BioPharma by 154.2% during the third quarter. Geode Capital Management LLC now owns 597,165 shares of the company’s stock worth $14,036,000 after acquiring an additional 362,221 shares during the period. State Street Corp raised its stake in ArriVent BioPharma by 210.4% during the 3rd quarter. State Street Corp now owns 476,809 shares of the company’s stock valued at $11,205,000 after purchasing an additional 323,186 shares during the last quarter. FMR LLC boosted its holdings in ArriVent BioPharma by 8.7% in the 3rd quarter. FMR LLC now owns 2,119,695 shares of the company’s stock valued at $49,813,000 after purchasing an additional 169,514 shares during the period. Finally, Suvretta Capital Management LLC grew its position in ArriVent BioPharma by 7.7% in the 3rd quarter. Suvretta Capital Management LLC now owns 1,845,162 shares of the company’s stock worth $43,361,000 after purchasing an additional 132,459 shares during the last quarter. 9.48% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of ArriVent BioPharma in a research report on Friday, November 15th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, ArriVent BioPharma presently has a consensus rating of “Buy” and a consensus target price of $36.80.
ArriVent BioPharma Trading Down 2.2 %
AVBP opened at $24.85 on Wednesday. The firm’s fifty day moving average price is $28.22 and its two-hundred day moving average price is $25.69. ArriVent BioPharma, Inc. has a fifty-two week low of $14.35 and a fifty-two week high of $36.37.
About ArriVent BioPharma
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
Recommended Stories
- Five stocks we like better than ArriVent BioPharma
- What Are Treasury Bonds?
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Stock Splits, Do They Really Impact Investors?
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Want to see what other hedge funds are holding AVBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report).
Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
